Imo Ebong1, Sula Mazimba2, Khadijah Breathett3. 1. Department of Medicine, Division of Cardiovascular Medicine, University of California, Davis, CA, USA. 2. Department of Medicine, Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA. 3. Department of Medicine, Division of Cardiovascular Medicine, Sarver Heart Center, University of Arizona, 1501 North Campbell Avenue, PO Box 245046, Tucson, AZ, 85724, USA. kbreathett@shc.arizona.edu.
Abstract
PURPOSE OF REVIEW: Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation. RECENT FINDINGS: N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation. There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation.
PURPOSE OF REVIEW: Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation. RECENT FINDINGS: N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation. There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation.
Authors: Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2010-12-22 Impact factor: 8.790
Authors: Patrícia Lourenço; José Paulo Araújo; Cristiana Paulo; Joana Mascarenhas; Fernando Friões; Ana Azevedo; Paulo Bettencourt Journal: Clin Cardiol Date: 2010-11 Impact factor: 2.882
Authors: James C Fang; Gregory A Ewald; Larry A Allen; Javed Butler; Cheryl A Westlake Canary; Monica Colvin-Adams; Michael G Dickinson; Phillip Levy; Wendy Gattis Stough; Nancy K Sweitzer; John R Teerlink; David J Whellan; Nancy M Albert; Rajan Krishnamani; Michael W Rich; Mary N Walsh; Mark R Bonnell; Peter E Carson; Michael C Chan; Daniel L Dries; Adrian F Hernandez; Ray E Hershberger; Stuart D Katz; Stephanie Moore; Jo E Rodgers; Joseph G Rogers; Amanda R Vest; Michael M Givertz Journal: J Card Fail Date: 2015-05-04 Impact factor: 5.712
Authors: Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Tomoko S Kato; Elias Collado; Tuba Khawaja; Yumeko Kawano; Margaret Kim; Maryjane Farr; Donna M Mancini; P Christian Schulze Journal: Circ Heart Fail Date: 2012-11-30 Impact factor: 8.790
Authors: Gregg C Fonarow; William F Peacock; Tamara B Horwich; Christopher O Phillips; Michael M Givertz; Margarita Lopatin; Janet Wynne Journal: Am J Cardiol Date: 2007-12-03 Impact factor: 2.778
Authors: Michele Emdin; Alberto Aimo; Giuseppe Vergaro; Antoni Bayes-Genis; Josep Lupón; Roberto Latini; Jennifer Meessen; Inder S Anand; Jay N Cohn; Jørgen Gravning; Lars Gullestad; Kaspar Broch; Thor Ueland; Ståle H Nymo; Hans-Peter Brunner-La Rocca; Rudolf A de Boer; Hanna K Gaggin; Andrea Ripoli; Claudio Passino; James L Januzzi Journal: J Am Coll Cardiol Date: 2018-11-06 Impact factor: 24.094
Authors: Hendra Setiadi; Ahmed M El-Banayosy; Susan George; David W Schmidtke; Aly El-Banayosy; Douglas A Horstmanshof; James W Long Journal: ASAIO J Date: 2021-11-10 Impact factor: 3.826